RU2006146207A - Биомаркеры для предсказания чувствительности к лечению клозапином - Google Patents
Биомаркеры для предсказания чувствительности к лечению клозапином Download PDFInfo
- Publication number
- RU2006146207A RU2006146207A RU2006146207/13A RU2006146207A RU2006146207A RU 2006146207 A RU2006146207 A RU 2006146207A RU 2006146207/13 A RU2006146207/13 A RU 2006146207/13A RU 2006146207 A RU2006146207 A RU 2006146207A RU 2006146207 A RU2006146207 A RU 2006146207A
- Authority
- RU
- Russia
- Prior art keywords
- patient
- slc6a3
- gene
- alleles
- clozapine
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title claims abstract 7
- 230000035945 sensitivity Effects 0.000 title claims abstract 6
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims abstract 16
- 229960004170 clozapine Drugs 0.000 claims abstract 16
- 101150085000 SLC6A3 gene Proteins 0.000 claims abstract 15
- 108700028369 Alleles Proteins 0.000 claims abstract 12
- 206010065604 Suicidal behaviour Diseases 0.000 claims abstract 12
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 claims abstract 7
- 238000000034 method Methods 0.000 claims abstract 6
- 102000005029 SLC6A3 Human genes 0.000 claims abstract 5
- 210000001124 body fluid Anatomy 0.000 claims abstract 4
- 239000010839 body fluid Substances 0.000 claims abstract 4
- 108020005345 3' Untranslated Regions Proteins 0.000 claims abstract 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract 3
- 102220284259 rs1379395211 Human genes 0.000 claims abstract 3
- 101001003569 Homo sapiens LIM domain only protein 3 Proteins 0.000 claims abstract 2
- 101000639972 Homo sapiens Sodium-dependent dopamine transporter Proteins 0.000 claims abstract 2
- 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 claims abstract 2
- 108091036066 Three prime untranslated region Proteins 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract 2
- 201000000980 schizophrenia Diseases 0.000 claims abstract 2
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 239000003550 marker Substances 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229930091051 Arenine Natural products 0.000 abstract 1
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57713104P | 2004-06-04 | 2004-06-04 | |
| US60/577,131 | 2004-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006146207A true RU2006146207A (ru) | 2008-07-20 |
Family
ID=34970966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006146207/13A RU2006146207A (ru) | 2004-06-04 | 2005-06-03 | Биомаркеры для предсказания чувствительности к лечению клозапином |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090281090A1 (https=) |
| EP (1) | EP1756314A1 (https=) |
| JP (1) | JP2008505060A (https=) |
| CN (1) | CN1973051A (https=) |
| AU (1) | AU2005250142B2 (https=) |
| BR (1) | BRPI0510775A (https=) |
| CA (1) | CA2568729A1 (https=) |
| MX (1) | MXPA06014127A (https=) |
| RU (1) | RU2006146207A (https=) |
| WO (1) | WO2005118848A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008136995A1 (en) * | 2007-04-30 | 2008-11-13 | The Ohio State University Research Foundation | Polymorphisms in genes affecting dopamine transporter disorders and uses thereof |
| US7932042B1 (en) | 2010-10-13 | 2011-04-26 | Suregene, Llc | Methods and compositions for the treatment of psychotic disorders through the identification of the olanzapine poor response predictor genetic signature |
| WO2012167281A2 (en) * | 2011-06-02 | 2012-12-06 | Gareth Davies | Clinical application utilizing genetic data for effective medication management |
| WO2014023852A1 (en) | 2012-08-10 | 2014-02-13 | Istituto Superiore di Sanità | Biomarkers |
| CN112195230B (zh) * | 2020-09-17 | 2022-08-23 | 青岛大学附属医院 | 一种用于氯氮平个体化用药指导的基因检测试剂、试剂盒、检测方法及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2381525A (en) * | 2001-11-01 | 2003-05-07 | Tcs Cellworks Ltd | Regulating gene expression |
| IL163645A0 (en) * | 2002-02-21 | 2005-12-18 | Idgene Pharmaceuticals Ltd | Association of snps in the comt locus and neighboring loci with schizophrenia, bipolar disorder, breast cancer and colorectal cancer |
| AU2003231897A1 (en) * | 2002-06-03 | 2003-12-19 | Idgene Pharmaceuticals Ltd. | Association of snps in the dgcr2 locus and neighboring loci with schizophrenia |
| WO2004074513A1 (en) * | 2003-02-21 | 2004-09-02 | Novartis Ag | Methods for the prediction of suicidality during treatment |
-
2005
- 2005-06-03 CA CA002568729A patent/CA2568729A1/en not_active Abandoned
- 2005-06-03 WO PCT/EP2005/006002 patent/WO2005118848A1/en not_active Ceased
- 2005-06-03 RU RU2006146207/13A patent/RU2006146207A/ru not_active Application Discontinuation
- 2005-06-03 BR BRPI0510775-0A patent/BRPI0510775A/pt not_active IP Right Cessation
- 2005-06-03 MX MXPA06014127A patent/MXPA06014127A/es not_active Application Discontinuation
- 2005-06-03 US US11/571,001 patent/US20090281090A1/en not_active Abandoned
- 2005-06-03 CN CNA2005800178554A patent/CN1973051A/zh active Pending
- 2005-06-03 AU AU2005250142A patent/AU2005250142B2/en not_active Ceased
- 2005-06-03 JP JP2007513872A patent/JP2008505060A/ja active Pending
- 2005-06-03 EP EP05754261A patent/EP1756314A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA06014127A (es) | 2007-01-31 |
| EP1756314A1 (en) | 2007-02-28 |
| BRPI0510775A (pt) | 2007-11-20 |
| AU2005250142A1 (en) | 2005-12-15 |
| AU2005250142B2 (en) | 2008-08-21 |
| WO2005118848A1 (en) | 2005-12-15 |
| CA2568729A1 (en) | 2005-12-15 |
| JP2008505060A (ja) | 2008-02-21 |
| US20090281090A1 (en) | 2009-11-12 |
| CN1973051A (zh) | 2007-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vrgoc et al. | Interleukin‐17 and Toll‐like Receptor 10 genetic polymorphisms and susceptibility to large joint osteoarthritis | |
| JP6120944B2 (ja) | 新規のインターフェロン−λ４（ＩＦＮＬ４）タンパク質、関連の核酸分子、並びにそれらの使用 | |
| Borovská et al. | Alu RNA fold links splicing with signal recognition particle proteins | |
| KR20160111925A (ko) | 자살 위험과 연관된 유전적 마커 및 그의 사용 방법 | |
| RU2006146207A (ru) | Биомаркеры для предсказания чувствительности к лечению клозапином | |
| CN114891873A (zh) | 一组评估主动脉夹层风险的生物标志物及其应用 | |
| CN103710448B (zh) | 一种预测强直性脊柱炎易感性的方法和试剂盒 | |
| Hellquist et al. | Identification of MAMDC1 as a candidate susceptibility gene for systemic lupus erythematosus (SLE) | |
| CN103710447B (zh) | 一种预测强直性脊柱炎易感性的方法和试剂 | |
| JP2008505060A5 (https=) | ||
| KR101914183B1 (ko) | Tmem182 유전자 다형성을 이용한 복부비만의 예후 또는 위험도를 평가하는 방법 및 키트 | |
| JP4197623B2 (ja) | インターフェロンの治療効果を予測するための新規多型マーカー、プライマー、プローブおよびインターフェロンの治療効果を予測する方法 | |
| CN103882112B (zh) | 一种预测强直性脊柱炎易感性的试剂及方法 | |
| CN103882111B (zh) | 一种预测强直性脊柱炎易感性的试剂 | |
| KR101757108B1 (ko) | 전장유전체연관분석방법을 이용한 단일염기다형성에 의한 심방세동의 예측 또는 진단에 관한 정보 제공 방법 | |
| KR20220025985A (ko) | 만성 감각신경성 이명 진단용 snp 마커 및 이를 이용한 진단 방법 | |
| KR101883657B1 (ko) | 단일염기다형성에 의한 심방세동의 예측 또는 진단에 관한 정보 제공 방법 | |
| CN103695549B (zh) | 预测强直性脊柱炎易感性的试剂 | |
| KR20160148807A (ko) | 장 베체트병 진단용 바이오마커 및 이의 용도 | |
| CN103215259A (zh) | 一种预测强直性脊柱炎易感性的方法和试剂盒 | |
| JP6788879B2 (ja) | 末梢動脈疾患検査方法及び検査用試薬 | |
| JP5644009B2 (ja) | 一塩基多型を用いた炎症性疾患の判定方法 | |
| KR102409336B1 (ko) | 면역글로불린 a 신병증 및 혈관염 진단용 snp 마커 및 이를 이용한 진단 방법 | |
| JP5656159B2 (ja) | インターフェロン療法の効果予測用マーカー | |
| CN108251519B (zh) | 轴前多指病的致病基因及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100112 |